Mk-0893 clinical trials
Also written MK-0893.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses mk-0893 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MK-0893
- 4
Studies by the year they started
5 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses mk-0893 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)CompletedPhase 2Merck Sharp & Dohme LLCNCT02004886Written as MK-0893
- A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)CompletedPhase 2Merck Sharp & Dohme LLCNCT00631488Written as MK-0893
- Dose-Range Finding Study for MK0893 (0893-008)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00479466Written as MK0893
- A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT02012166Written as MK-0893 10 mg
- A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)CompletedPhase 1Merck Sharp & Dohme LLCNCT00902161Written as MK0893
Codes
What other systems call mk-0893 · ClinicalTrials.gg INT006149
- UNII (FDA) CCP2U6LWTPMK-0893Confirmed NLM, Wikidata
- Wikidata Q27086715mk-0893Confirmed NLM, Wikidata
- DrugBank DB12044One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CCP2U6LWTP | MK-0893 | Confirmed NLM, Wikidata |
| Wikidata | Q27086715 | mk-0893 | Confirmed NLM, Wikidata |
| DrugBank | DB12044 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.